Overview
Altimmune Q3 revenue and net income beat analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting improved financial performance
Company strengthens executive team with key appointments
Outlook
Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025
Company to hold End-of-Phase 2 meeting with FDA in Q4 2025
Topline results from RECLAIM trial in AUD expected in 2026
Result Drivers
Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $5,000 | $600 (8 Analysts) |
Q3 EPS | Beat | -$0.21 | -$0.27 (9 Analysts) |
Q3 Net Income | Beat | -$19.01 mln | -$23.60 mln (8 Analysts) |
Q3 Income from Operations | Beat | -$20.86 mln | -$25.50 mln (8 Analysts) |
Q3 Basic EPS | -$0.21 | ||
Q3 Operating Expenses | $20.86 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75
Press Release: ID:nGNX21Cg96
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)